◼ Archived
Health
🔮 fades ✓
GLP-1 Drugs May Have a Hidden Effect on Your Eyes, Study Finds
New safety guidance and a lawsuit spotlight a possible eye‑risk link in popular GLP-1 weight‑loss drugs.
Glp-1
27 independently sourced, verified trend briefs about this subject.
What this topic page includes
Newsylist includes a story here only after at least four independent sources support it and its brief passes the verification check. The qualifying coverage spans 2 news categories, from Jun 25, 2026 through Aug 6, 2026.
The cards below are ordered newest first. Each opens the underlying timeline, source list, coverage velocity and verification context; raw or extractive-only records are excluded.
◼ Archived
Health
🔮 holds ✗
GLP-1 weight loss drugs: What experts say about keeping weight off after stopping
Use of GLP-1 weight loss medications has reached a new high in the United States, sparking debate over long-term efficacy and accessibility.
◼ Archived
Health
🔮 holds ✗
One in eight U.S. adults uses GLP-1 drugs; Medicare now opens weight-loss access
Medicare now provides access to GLP-1 weight-loss drugs as utilization rates among U.S. adults reach one in eight.
◼ Archived
Business
🔮 holds ✗
Compounded GLP-1 drugs creating concern among doctors and FDA
Compounded GLP-1 weight‑loss drugs face mounting scrutiny as doctors and regulators flag safety concerns.
◼ Archived
Health
🔮 holds ✗
Weight-loss jab users warned about relationship side effect no one prepares you for
GLP‑1 weight‑loss drugs are reshaping women’s marriage prospects and job markets, while sparking warnings about unseen relationship strain.
◼ Archived
Health
🔮 holds ✓
Scientists Searching 6,000 Drugs For Anti-Aging Properties Found One Hiding in Plain Sight
Researchers identify existing medications, including GLP-1 drugs and nasal sprays, as potential candidates for slowing biological aging processes.
◼ Archived
Health
🔮 holds ✗
Should We Be Concerned About Muscle Loss With GLP-1s?
Concerns are rising over potential muscle loss and frailty in older adults using GLP-1 weight loss medications.
◼ Archived
Health
🔮 holds ✗
Rare eye disorder linked to Ozempic-like medications
Regulators and health advisors are warning of a rare but severe risk of vision loss associated with GLP-1 weight-loss medications.
◼ Archived
Health
🔮 fades ✗
GLP-1 drugs linked to 17% drop in worker sick leave, new economic study finds
A new economic study suggests a correlation between the use of GLP-1 weight-loss drugs and a 17% reduction in employee sick leave.
◼ Archived
Business
🔮 holds ✓
Novo sues Lilly, claiming misleading ads in weight-loss drug battle
Novo Nordisk has filed a lawsuit against Eli Lilly over allegations of false and misleading advertising regarding weight-loss drug efficacy.
◼ Archived
Business
🔮 fades ✗
Novo Nordisk sues Eli Lilly, alleging misleading GLP-1 advertising
Novo Nordisk has filed a lawsuit against Eli Lilly, alleging the company used deceptive and false advertising regarding GLP-1 weight-loss medications.
◼ Archived
Health
🔮 holds ✓
24 GLP-1 Users Reveal The Good, The Bad, And The Shocking Side Effects
GLP-1 weight-loss medications are seeing a massive surge in adoption, sparking debates over side effects and social disclosure.
◼ Archived
Health
🔮 holds ✗
People Can Lose Their Zest for Life After Starting GLP-1s, Docs Warn
Medical professionals are warning that GLP-1 medications may cause some patients to experience emotional flatness and a loss of 'zest for life.'
◼ Archived
Health
🔮 holds ✗
GLP-1’s Reduce Binge Eating Symptoms
New evidence suggests GLP-1 medications, including Ozempic and Wegovy, may serve as a promising treatment for binge eating disorder.
◼ Archived
Health
🔮 holds ✗
Does stopping a GLP-1 really doom you to regain all the weight?
Recent studies examine the long-term impact of discontinuing GLP-1 weight-loss medications like Ozempic and Wegovy.
◼ Archived
Business
🔮 holds ✗
Why your health plan doesn’t cover GLP-1s, according to a top insurance exec
Rising demand for GLP-1 weight-loss medications is straining budgets and prompting insurers and employers to limit coverage.
◼ Archived
Health
🔮 holds ✗
New weight loss pill that’s beating oral Ozempic
New oral GLP-1 receptor agonists are emerging as powerful alternatives to existing weight-loss medications in recent clinical trials.
◼ Archived
Business
🔮 fades ✓
A tiny GLP-1 implant is the latest bet to help patients maintain their weight loss
Novo Nordisk and Vivani have announced a partnership to develop a long-acting semaglutide implant designed to assist with long-term weight loss.
◼ Archived
Health
🔮 holds ✓
Wegovy weight loss pill now available in UK
The Wegovy weight loss pill has launched in the UK, marking the arrival of the first daily oral GLP-1 medication for weight management.
◼ Archived
Business
🔮 holds ✓
Eli Lilly's Market Cap Balloons, Again, On This IPO's Setback
Eli Lilly's market capitalization has risen following a setback for Kailera's oral GLP-1 obesity drug trials in China.
◼ Archived
Health
🔮 fades ✓
How easy is it to get weight-loss drugs online? Secret shoppers from Yale found out.
Secret shoppers from Yale have revealed the alarming ease of obtaining GLP-1 weight-loss drugs from online vendors without traditional doctor consultations.
◼ Archived
Health
🔮 holds ✗
People Are Sharing The Things They Think Will Be “Inevitable Outcomes” Of GLP-1s Over The Next 20 Years
Social media discourse and academic research are converging on the long-term societal and psychological impacts of GLP-1 medications.
◼ Archived
Health
🔮 holds ✗
Peptide hype is at an all-time high
Peptides are surging in popularity for weight loss and muscle growth, but reports indicate a dangerous rise in unapproved and grey-market usage.
◼ Archived
Health
🔮 holds ✗
As weight loss drugs like Ozempic spread, Louisiana doctors, researchers help answer big questions
Medical researchers and clinicians are investigating whether GLP-1 weight loss drugs like Ozempic offer benefits beyond weight reduction, including longevity.
◼ Archived
Business
🔮 holds ✗
Seniors in Medicare are about to get landmark obesity drug coverage
Medicare is set to provide coverage for GLP-1 obesity medications starting July 1, reducing costs to $50 a month for qualifying seniors.
◼ Archived
Business
🔮 holds ✗
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 June 2026
Eli Lilly shares surge following a CHMP recommendation for Jaypirca's EU approval to treat chronic lymphocytic leukemia.
◼ Archived
Health
🔮 holds ✗
Eli Lilly and Company (LLY) CEO on How GLP-1s Will Reshape America
Eli Lilly's CEO outlines the transformative potential of GLP-1s as new oral weight-loss medications enter development.